What Researchers Did
Researchers investigated the molecular mechanisms and host-microbiome response to hyperbaric oxygen therapy (HBOT) in ulcerative colitis patients using a multi-omic approach on pre- and post-intervention samples from clinical trials.
What They Found
HBOT reduced host neutrophil STAT3 and azurophilic granule activity in ulcerative colitis patients. It also decreased microbial diversity, specifically reducing mucus-adherent taxa, while increasing Firmicutes and MUC2 levels, and showed associations with Akkermansia muciniphila.
Canadian Relevance
This study was not conducted in Canada and does not have a direct Canadian connection.
Study Limitations
As a phase 2 clinical trial, this study's findings require confirmation in larger, randomised controlled trials to establish broader generalizability and long-term efficacy.